

Sponsored

Strong first half lifts Invion's (ASX:IVX) hopes for Photosoft technology development as it prepares for clinical trials

February 23, 2022 06:26 PM AEDT

[Be the First to Comment](#)



[Anam Siddiqui](#)
Author



[Shwetambri Chauhan](#)
Reviewer

More on:

[Invion Limited](#)

MOST READ

[Stock Market](#)

[Here's why HomeCo Daily Needs REIT \(ASX:HDN\) is in the news today](#)

[Stock Market](#)

[Why are consumer stocks COL, EVD, WES garnering investors' attention today](#)

[Economy](#)

[Australian Election 2022: AHHA calls for value-based approach to healthcare system](#)



Image source: IVX Presentation, dated 3 February 2022

Ad

Kalkine

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Name


Email

+61 Phone

DOWNLOAD FREE REPORT

By submitting your details and clicking on the button above to receive the free report, you agree to our [Terms and Conditions](#) and consent to receive marketing offers including to be contacted by email or phone as set out in our [Privacy Policy](#). Any calls will be made by Kalkine Pty Ltd (Kalkine) or Kalkine Solutions Private Limited (KSPL) on our behalf. You also agree that Kalkine/KSPL can give you its Financial Services Guide by electronic means (including by website link or email). Before reading the free report, please read the Financial Services Guide available [here](#).

You May Like



We're offline

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy

OK

Highlights

- Invion's progress during the first half was marked by Proof-of-Concept studies, expansion of territories and AU\$12.1 million capital raising.
- Proof-of-Concept (PoC) studies showed a complete regression of triple negative breast cancer (TNBC) in vivo following INV043 treatment.
- Expansion of the exclusivity agreement with RMW Cho Group gives Invion access to markets with more than 2.8 billion people.
- The Company is making pre-clinical preparations with a view to initiating clinical trials in more than one indication in 2022.

[→ Are You Looking for Compelling Stock Ideas from Diverse Sectors? Get Access to Kalkine's Investor/Resource Reports on a 7 days' Free Trial.](#)

Invion Limited ([ASX:IVX](#)) has released its report for the first half of the financial year 2022, outlining major activities and significant developments by the life sciences company as it prepares to commence human trials later this year.

Invion is focused on the global research & development of Photosoft™ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases. During the reported period, the Company made significant progress in proving up its Active Pharmaceutical Ingredient (API) INV043 and expanding its exclusive rights to the technology across multiple markets.

GOOD WATCH: [Invion expands Photosoft™ technology territory for cancer and related diseases](#)

Encouraging Proof-of-Concept study outcomes

Invion's research partner and world-leading research organisation, Hudson Institute of Medical Research carried out the latest Proof-of-Concept (PoC) studies, highlighting a complete regression of triple negative breast cancer (TNBC) in vivo following INV043 treatment.

The pilot study used INV043 to treat immunocompetent mice that had been implanted with TNBC.

[Sponsored](#)

[Have you tracked these 3 key developments from Empire Resources \(ASX:ERL\) in February 2022?](#)

February 23, 2022 03:18 PM AEDT | [Mohammad Zaid](#)

[Cryptocurrency](#)

[Ethereum exchange balance at 3-month high. What does it mean for investors?](#)

February 23, 2022 05:32 PM AEDT | [Daniel Paul Johns](#)

[Economy](#)

[New Zealand central bank raises OCR by 25 bps, says more tightening ahead](#)

February 23, 2022 05:00 PM AEDT | [Manika](#)

[Communication Stocks](#)

[Spark \(ASX:SPK\) maintains dividend as mobile drives revenue growth](#)

February 23, 2022 04:20 PM AEDT | [Samta](#)

[Stock Market](#)

[Coles Group \(ASX:COL\) in hot water as workers strike over jobs and benefits](#)

November 19, 2020 03:22 PM AEDT | [Kunal Sawhney](#)

Recent Articles


[Cryptocurrency](#)

[Which unique features](#)



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy

OK



Source: IVX Presentation, dated 3 February 2022

Moreover, TNBC could not be re-established in treated mice, indicating that the treatment could have triggered an immune response. Further, there was no apparent scarring or other indication of prior tumour presence, and no evidence of either primary tumour or metastatic spread at autopsy.

ALSO READ: [All you need to know about Invion's \(ASX:IVX\) journey to develop cancer treatment](#)

Expansion of territories widens Invion's footprint

Another significant development in 1H FY22 was the expansion of the Company's exclusivity agreement with RMW Cho Group, the developer of Photosoft™ technology. The agreement will give Invion access to markets with over 2.8 billion people.

Under the new agreement, both parties will co-develop Photosoft™ for cancer and related diseases (Indications), pursuant to which Invion will gain exclusive distribution rights to the technology in Asia Pacific (Territory) for the Indications.

ALSO READ: [A deep dive into Invion's \(ASX:IVX\) opportunities in cancer and AID space](#)

Capital raising to advance Invion's endeavours

Invion undertook a capital raising program including a share placement and a share purchase plan (SPP), raising AU\$12.1 million. The new shares were priced at 2.2 cents per share with one free attaching option for every two new shares. The options, exercisable at 4 cents, are due for expiry in 18 months from the issue date.

The capital raised is planned to be used to fund the expanded agreement and working capital.

ALSO READ: [Invion revs up Photosoft™ technology development with capital](#)



Search by keyword or Code



AUS

[Australia sees strong wage growth in December 2021 quarter](#)


February 23, 2022 02:38 PM AEDT | Akanksha Vashisht

[Cryptocurrency](#)

[Crypto Catch: Bitcoin up nearly 2%, regains US\\$38k level](#)

February 23, 2022 02:18 PM AEDT | Daniel Paul Johns

Latest Videos



[Understanding the scope of mining industry! | Expert Talk with Arvind Misra](#)



[3 ASX Defence Stocks On Investors'](#)



[Is the Queen](#)



[ASX rises;](#)



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy

OK

Invion is leveraging its initial success in the preparation to commence clinical trials using its technology to treat cancers while also advancing its research into atherosclerosis and infectious diseases. Cancer remains the primary focus for the Company's clinical development.

The Company and its research partners, Hudson Institute and the Peter MacCallum Cancer Centre, are identifying target cancer indications for the clinical trials. Further details are expected before FY22 end.

Meanwhile, Hudson Institute is working on further PoC studies, including a larger TNBC study (primary tumour model) and a secondary study investigating the potential of INV043 using a metastatic model. The results from these studies are expected in the coming half year.

ALSO READ: [Invion closes December quarter on firm financial footing and promising drug development outlook](#)

The efforts would underpin the initiation of clinical trials on more than one cancer indication by the end of 2022. Initial clinical trials would focus on anogenital cancer and basal cell carcinoma (BCC), which accounts for most skin cancers in Australia.

Invion also expects to release findings from early-stage discovery work on atherosclerosis and infectious diseases in 2022. The results from this work will enable the Company to identify specific areas of the diseases to target before it commences proof-of-concept studies on the targeted indications.

IVX shares traded at AU\$0.017 on 23 February 2022.

Trending Words

[Factor Endowment](#)

[Aggregate Market Value \(AMV\)](#)

[Exchange-Traded Funds](#)

[Mutual fund](#)

[Macroeconomic Indicators](#)

[Chief Executive Officer \(CEO\)](#)

Disclaimer

[Read More](#)

Speak your Mind

Add a comment

Enter your display name

POST COMMENT



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy

OK

Featured Articles



[Sponsored](#)

[Strong first half lifts Invion's \(ASX:IVX\) hopes for Photosoft technology development as it prepares for clinical trials](#)

February 23, 2022 06:26 PM AEDT | [Anam Siddiqui](#)



[Sponsored](#)

[Agua Resources' \(ASX:AGR\) Pampafos® beats chemical fertilisers; What's Ahead?](#)


February 23, 2022 02:03 PM AEDT | [Anam Siddiqui](#)



[Sponsored](#)

[Agua Resources \(ASX:AGR\) kicks off infill drilling at Andrade Copper Project](#)

February 23, 2022 01:58 PM AEDT | [Mohammad Zaid](#)



[Sponsored](#)

[How is EarlyBirds helping businesses tap opportunities in 3D printing space?](#)


February 23, 2022 11:41 AM AEDT | [Mohammad Zaid](#)



[Sponsored](#)

[Ora Banda \(ASX:OBM\) looks to raise AU\\$20 million under equity raising](#)

February 22, 2022 08:01 PM AEDT | [Mohammad Zaid](#)



[Sponsored](#)

[Gold hunt on cards for King River Resources' \(ASX:KRR\) 2022 game plan](#)

February 22, 2022 06:39 PM AEDT | [Anam Siddiqui](#)

TOP ASX LISTED COMPANIES

[BHP Group Limited \(ASX:BHP\)](#)

[Wesfarmers Limited \(ASX:WES\)](#)

[Woodside Petroleum Limited \(ASX:WPL\)](#)

[Coles Group Limited \(ASX:COL\)](#)

[Rio Tinto \(ASX:RIO\)](#)

[Woolworths Group Ltd \(ASX:WOW\)](#)

[ResMed Inc \(ASX:RMD\)](#)

[Sydney Airport \(ASX:SYD\)](#)

[Commonwealth Bank of Australia \(ASX:CBA\)](#)

[Macquarie Group Limited \(ASX:MQG\)](#)

[Goodman Group \(ASX:GMG\)](#)

[Brambles Limited \(ASX:BXB\)](#)

[Westpac Banking Corporation \(ASX:WBC\)](#)

[Telstra Corporation Limited \(ASX:TLS\)](#)

[Newcrest Mining Limited \(ASX:NCM\)](#)

[Amcor PLC \(ASX:AMC\)](#)

[Australia and New Zealand Banking Group Limited \(ASX:ANZ\)](#)

[Transurban Group \(ASX:TCL\)](#)

[Aristocrat Leisure Limited \(ASX:ALL\)](#)

[Insurance Australia Group Limited \(ASX:IAG\)](#)

[National Australia Bank Limited \(ASX:NAB\)](#)

[Fortescue Metals Group Limited \(ASX:FMG\)](#)

[Scentre Group \(ASX:SCG\)](#)

[Santos Limited \(ASX:STO\)](#)

POPULAR STOCKS

[Dividend Stocks](#)

[Penny Stocks](#)

[Lithium Stocks](#)

MARKET INDICES

[ASX 20](#)

[ASX 50](#)

[ASX 100](#)

QUICK LINKS

[Upcoming Dividend](#)

[Dividend Yield](#)

[Director's Interest](#)

GENERAL

[Our Events](#)

[Podcast](#)


[Archive](#)

CONTACT

[Subscribe](#)

[Sydney](#)

[Phone](#)



We're offline

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

OK

[Cannabis Stocks](#)

[All Ordinaries](#)

[ETFs](#)

[Mining Stocks](#)

[Tech corner](#)

[Media Mentions](#)

FOLLOW US



DOWNLOAD APP




<#> [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#)
[Z](#)

[About Us](#) [Contact Us](#) [Meet The Team](#) [Disclaimer](#) [Terms of Use](#) [Privacy Policy](#) [Web Content Policy](#) [Cookie Policy](#)

Copyright © 2022 Kalkine Media Pty Ltd. All Rights Reserved.

ACN:629 651 672 ABN:84 629 651 672



We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy

OK